Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study

BACKGROUND: Regorafenib, a multitargeted tyrosine kinase inhibitor, proved to be active in patients with soft tissue sarcomas (STS). METHODS: We conducted an open-label, non-randomized, single-center phase II study in advanced pretreated STS patients. Patients received regorafenib 160 mg daily on da...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Medicine (Baltimore)
Main Authors: Marrari, Andrea, Bertuzzi, Alexia, Bozzarelli, Silvia, Gennaro, Nicolò, Giordano, Laura, Quagliuolo, Vittorio, De Sanctis, Rita, Sala, Simona, Balzarini, Luca, Santoro, Armando
Format: Artigo
Jezik:Inglês
Izdano: Wolters Kluwer Health 2020
Teme:
5700
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7328961/
https://ncbi.nlm.nih.gov/pubmed/32590747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000020719
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki